{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:59:08Z","timestamp":1790629148588,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Increased level of circulating myeloid\n-derived suppressor cells (MDSCs) in colorectal cancer (CRC) patients has been associated with higher tumor stage and poorer survival due to poorer response to therapeutic agents. However, studies reported inconsistent results on how chemotherapeutic agents affecting the depletion of two major types of MDSCs, polymophonuclear MDSC (PMN-MDSC) and monocytic MDSC (M-MDSC). The present study aims to learn deeper on the dynamic changes of circulating MDSCs, especially in response to oxaliplatin-based treatment in CRC patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a prospective study that recruited 30 treatment-naive patients with varying stages of CRC who were scheduled to receive oxaliplatin-based chemotherapy. Blood sampling was conducted prior to and at several time points during and after chemotherapy. Multicolor flow cytometry assay was used to analyse the proportion of HLA-DR<jats:sup>\u2013<\/jats:sup> and CD33<jats:sup>+<\/jats:sup> with CD15<jats:sup>+<\/jats:sup> (PMN-MDSCs) or CD14<jats:sup>+<\/jats:sup> (M-MDSCs) cells within peripheral blood mononuclear cells (PBMCs). Other essential tumor biomarkers such as carcinoembryonic antigen (CEA) and tumor-infiltrating lymphocytes (TILs) were also assessed. As a control, 14 healthy subjects were recruited in this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Indonesian treatment-naive CRC patients exhibited significantly higher circulating PMN-MDSCs compared to healthy subjects (<jats:italic>p<\/jats:italic>\u2009=\u20090.003), while M-MDSCs levels showed no significant difference between the groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.890). Following chemotherapy, the MDSCs level demonstrated dynamic changes. Interestingly, a subgroup of CRC patients with decreased in both PMN- and M-MDSCs levels on D-14 of chemotherapy consistently showed a significant reduction in MDSCs levels during and after therapy completion compared to baseline (<jats:italic>p<\/jats:italic>\u2009=\u20090.0078).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Circulating MDSCs level, particularly PMN-MDSCs, in CRC patients, was significantly higher compared to healthy subjects. Changes in both circulating PMN- and M-MDSCs levels at D-14 chemotherapy might have prognostic value in oxaliplatin-based chemotherapy.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12029-025-01207-x","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:52:54Z","timestamp":1743288774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Dynamic Changes of Circulating Myeloid-Derived Suppressor Cells (MDSCs) Subsets in Colorectal Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy"],"prefix":"10.1007","volume":"56","author":[{"given":"Ralph Girson","family":"Gunarsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aru Wisaksono","family":"Sudoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricci","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilafitria","family":"Fauza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajar Lamhot","family":"Gultom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Basir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dicky","family":"Kurniawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akterono Dwi","family":"Budiyati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"3","key":"1207_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1207_CR3","doi-asserted-by":"crossref","unstructured":"Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, ... Gibson F. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14(1):1\u201310.","DOI":"10.1016\/j.clcc.2014.11.002"},{"issue":"34","key":"1207_CR4","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.3748\/wjg.v24.i34.3834","volume":"24","author":"K Van der Jeught","year":"2018","unstructured":"Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834.","journal-title":"World J Gastroenterol"},{"key":"1207_CR5","doi-asserted-by":"publisher","first-page":"610104","DOI":"10.3389\/fonc.2020.610104","volume":"10","author":"K Yin","year":"2020","unstructured":"Yin K, Xia X, Rui K, Wang T, Wang S. Myeloid-derived suppressor cells: a new and pivotal player in colorectal cancer progression. Front Oncol. 2020;10:610104.","journal-title":"Front Oncol"},{"key":"1207_CR6","doi-asserted-by":"crossref","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, ... Pag\u00e8s F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20131964.","DOI":"10.1126\/science.1129139"},{"issue":"4","key":"1207_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.tranon.2018.03.008","volume":"11","author":"AC Eriksen","year":"2018","unstructured":"Eriksen AC, S\u00f8rensen FB, Lindebjerg J, Hager H, Christensen RD, Kj\u00e6r-Frifeldt S, Hansen TF. The prognostic value of tumor-infiltrating lymphocytes in stage II colon cancer. A nationwide population-based study Translational Oncology. 2018;11(4):979\u201387.","journal-title":"Transl Oncol"},{"issue":"5","key":"1207_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/modpathol.2010.234","volume":"24","author":"AM Dahlin","year":"2011","unstructured":"Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, \u00d6berg \u00c5, Ruteg\u00e5rd J, Palmqvist R. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol. 2011;24(5):671\u201382.","journal-title":"Mod Pathol"},{"key":"1207_CR9","doi-asserted-by":"crossref","unstructured":"Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, ... Zhao K. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PloS ONE. 2013;28(2):e57114.","DOI":"10.1371\/journal.pone.0057114"},{"key":"1207_CR10","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3389\/fimmu.2020.01526","volume":"11","author":"I Sieminska","year":"2020","unstructured":"Sieminska I, Baran J. Myeloid-derived suppressor cells in colorectal cancer. Front Immunol. 2020;11:1526.","journal-title":"Front Immunol"},{"key":"1207_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0674-1","volume":"7","author":"MC Apodaca","year":"2019","unstructured":"Apodaca MC, Wright AE, Riggins AM, Harris WP, Yeung RS, Yu L, Morishima C. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells. J Immunother Cancer. 2019;7:1\u201311.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"e1331807","DOI":"10.1080\/2162402X.2017.1331807","volume":"6","author":"Z Wang","year":"2017","unstructured":"Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6(7):e1331807.","journal-title":"Oncoimmunology"},{"key":"1207_CR13","doi-asserted-by":"crossref","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, ... Ghiringhelli F. (2010). 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell\u2013dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u20133061.","DOI":"10.1158\/0008-5472.CAN-09-3690"},{"key":"1207_CR14","doi-asserted-by":"crossref","unstructured":"Limagne E, Euvrard R, Thibaudin M, R\u00e9b\u00e9 C, Derang\u00e8re V, Chevriaux A, ... Ghiringhelli F. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX\u2013bevacizumab drug treatment regimen MDSC and Th17 in FOLFOX\u2013bevacizumab\u2013treated mCRC patients. Cancer Res. 2016;76(18):5241\u20135252.","DOI":"10.1158\/0008-5472.CAN-15-3164"},{"issue":"1","key":"1207_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/diseases9010021","volume":"9","author":"L Lakemeyer","year":"2021","unstructured":"Lakemeyer L, Sander S, Wittau M, Henne-Bruns D, Kornmann M, Lemke J. Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer. Diseases. 2021;9(1):21.","journal-title":"Diseases"},{"key":"1207_CR16","doi-asserted-by":"publisher","unstructured":"Syahruddin E, Wulandari L, Sri Muktiati N, Rima A, Soeroso N, Ermayanti S, ... & Utomo ARH. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. Lung Cancer: Targets Ther. 2018;25\u201334. https:\/\/doi.org\/10.2147\/LCTT.S154116.","DOI":"10.2147\/LCTT.S154116."},{"key":"1207_CR17","doi-asserted-by":"crossref","unstructured":"Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, ... Pages F. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20(7):1891\u20131899.","DOI":"10.1158\/1078-0432.CCR-13-2830"},{"key":"1207_CR18","doi-asserted-by":"publisher","unstructured":"Cassetta L, Bruderek K, Skrzeczynska-Moncznik J, Osiecka O, Hu X, Rundgren IM, ... Brandau S. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J Immunother Cancer. 2020;8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001223.","DOI":"10.1136\/jitc-2020-001223."},{"key":"1207_CR19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3389\/fimmu.2019.01401","volume":"10","author":"P Ma","year":"2019","unstructured":"Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer. Front Immunol. 2019;10:1401.","journal-title":"Front Immunol"},{"key":"1207_CR20","doi-asserted-by":"crossref","unstructured":"Lang, S., Bruderek, K., Kaspar, C., H\u00f6ing, B., Kanaan, O., Dominas, N., ... & Brandau, S. Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets. Clin Cancer Res. 2018;24(19):4834\u20134844.","DOI":"10.1158\/1078-0432.CCR-17-3726"},{"key":"1207_CR21","unstructured":"Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ, ... & Miao ZN. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World journal of gastroenterology: WJG. 2012;18(25):3303."},{"key":"1207_CR22","doi-asserted-by":"crossref","unstructured":"Siemi\u0144ska, I., W\u0119glarczyk, K., Walczak, M., Czerwi\u0144ska, A., Pach, R., Rubinkiewicz, M., ... & Baran, J. Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery. Transl Oncol. 2022;17:101346.","DOI":"10.1016\/j.tranon.2022.101346"},{"key":"1207_CR23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00262-008-0505-6","volume":"57","author":"C M\u00e9nard","year":"2008","unstructured":"M\u00e9nard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother. 2008;57:1579\u201387.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1207_CR24","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3390\/cancers15051563","volume":"15","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang M, Zhang Y, Liu K, Lu C. 5-Fluorouracil suppresses colon tumor through activating the p53-fas pathway to sensitize myeloid-derived suppressor cells to FasL+ cytotoxic t lymphocyte cytotoxicity. Cancers. 2023;15(5):1563.","journal-title":"Cancers"},{"issue":"1","key":"1207_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/cam4.1878","volume":"8","author":"NR Kim","year":"2019","unstructured":"Kim NR, Kim YJ. Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-\u03baB signaling. Cancer Med. 2019;8(1):276\u201388.","journal-title":"Cancer Med"},{"key":"1207_CR26","doi-asserted-by":"crossref","unstructured":"Van Wigcheren GF, De Haas N, Mulder TA, Horrevorts SK, Bloemendal M, Hins-Debree S, ... De Vries IJM. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. Oncoimmunology. 2021;10(1):1935557.","DOI":"10.1080\/2162402X.2021.1935557"},{"issue":"2","key":"1207_CR27","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.jhepr.2020.100224","volume":"3","author":"TT Kwong","year":"2021","unstructured":"Kwong TT, Wong CH, Zhou JY, Cheng ASL, Sung JJY, Chan AWH, Chan SL. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Reports. 2021;3(2):100224.","journal-title":"JHEP Reports"},{"issue":"2","key":"1207_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105\u201315.","journal-title":"Immunology"},{"key":"1207_CR29","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li C, Liu T, Dai X, Bazhin AV. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol. 2020;11:1371.","journal-title":"Front Immunol"},{"key":"1207_CR30","doi-asserted-by":"publisher","unstructured":"Dysthe M, Parihar R. Myeloid-derived suppressor cells in the tumor microenvironment. Tumor Microenvironment: Hematopoietic Cells\u2013Part A. 2020;117\u2013140. https:\/\/doi.org\/10.1007\/978-3-030-35723-8_8.","DOI":"10.1007\/978-3-030-35723-8_8."},{"key":"1207_CR31","doi-asserted-by":"crossref","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, ... Gabrilovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Commun. 2016;7(1):12150.","DOI":"10.1038\/ncomms12150"},{"key":"1207_CR32","doi-asserted-by":"crossref","unstructured":"Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, ... Gabrilovich DI. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Science Immunol. 2016;1(2):aaf8943-aaf8943.","DOI":"10.1126\/sciimmunol.aaf8943"},{"issue":"1","key":"1207_CR33","first-page":"233","volume":"30","author":"B Aldulaymi","year":"2010","unstructured":"Aldulaymi B, Christensen IJ, S\u00f6l\u00e9tormos G, Jess P, Nielsen SE, Br\u00fcnner N, Nielsen HJ. Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer. Anticancer Res. 2010;30(1):233\u20137.","journal-title":"Anticancer Res"},{"key":"1207_CR34","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00432-003-0492-0","volume":"129","author":"S Ohtsukasa","year":"2003","unstructured":"Ohtsukasa S, Okabe S, Yamashita H, Iwai T, Sugihara K. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol. 2003;129:719\u201326.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01207-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:53:07Z","timestamp":1743288787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01207-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01207-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"14 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethical Committee of the MRCCC Siloam Hospital (2105\/SS\/Dir\/XII\/2020) and performed in accordance with the principles of the revised Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"87"}}